Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Haemonetics (HAE) Net Margin (2016 - 2025)

Haemonetics has reported Net Margin over the past 17 years, most recently at 13.21% for Q4 2025.

  • Quarterly results put Net Margin at 13.21% for Q4 2025, up 245.0% from a year ago — trailing twelve months through Dec 2025 was 13.31% (up 384.0% YoY), and the annual figure for FY2025 was 12.32%, up 334.0%.
  • Net Margin for Q4 2025 was 13.21% at Haemonetics, up from 11.82% in the prior quarter.
  • Over the last five years, Net Margin for HAE hit a ceiling of 17.54% in Q1 2025 and a floor of 4.91% in Q2 2021.
  • Median Net Margin over the past 5 years was 9.72% (2023), compared with a mean of 8.63%.
  • Biggest five-year swings in Net Margin: plummeted -1678bps in 2021 and later soared 1159bps in 2025.
  • Haemonetics' Net Margin stood at 6.18% in 2021, then skyrocketed by 75bps to 10.78% in 2022, then decreased by -14bps to 9.29% in 2023, then increased by 16bps to 10.76% in 2024, then grew by 23bps to 13.21% in 2025.
  • The last three reported values for Net Margin were 13.21% (Q4 2025), 11.82% (Q3 2025), and 10.6% (Q2 2025) per Business Quant data.